Cramer's Morning Take: Bristol Myers & Eli Lilly 11/25/24
Nov 25, 2024
auto_awesome
Jim and Jeff dive into the biopharmaceutical landscape, spotlighting Bristol-Myers' groundbreaking schizophrenia drug and its investment implications. They also discuss the looming patent cliffs that could reshape earnings forecasts by 2028. The conversation veers into the financial outlook for major players like Bristol-Myers and Eli Lilly, exploring revenue potential linked to new drug approvals amidst the challenges of product development. It's an insightful take on the pharmaceutical market dynamics and investment strategies.
Investors are encouraged to diversify portfolios by incorporating alternative assets to enhance long-term financial success.
Bristol-Myers' new schizophrenia drug represents a breakthrough in treatment, offering significant revenue potential and investment opportunities.
Deep dives
Investment Strategies in Alternative Assets
A focus on diversifying investment portfolios highlights the advantages of alternative assets. By leveraging expertise in both liquid and illiquid strategies, investors can enhance their chances of achieving long-term financial goals. PGM's management of over $320 billion in such assets across public and private markets demonstrates its commitment to helping clients navigate the complexities of today’s investment landscape. This approach enables investors to capitalize on opportunities in emerging markets and sectors, ensuring a robust and varied portfolio.
Breakthroughs in Pharmaceutical Innovation
Bristol-Myers has made a significant advancement in mental health treatment with the approval of a schizophrenia drug, marking a historical milestone in over three decades. Unlike existing medications that often lead to distressing side effects like weight gain, this new drug shows promise for patients, potentially addressing both schizophrenia and bipolar disorder. Financial analysts project substantial revenue potential, estimating earnings to reach around $20 billion if it gains approval for further indications. This innovative breakthrough not only signifies a leap in medical treatment but also presents exciting investment opportunities amidst challenges such as impending patent expirations.
1.
Investment Insights: Bristol-Myers and Its Game-Changing Schizophrenia Drug
Jim and Jeff discuss why they’re buying this biopharmaceutical stock. They also talk about adding to this pharmaceutical stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake